Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing ...

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive ...

Thirteen years after cervical cancer, I’ve found strength in healing, grief in silence, and hope in sharing the quiet truths ...

I found a lump and was shocked to learn it was breast cancer, but over 22 years I’ve learned healing takes time, asking for ...

Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during ...

After nearly 11 years of living with Hodgkin lymphoma, my sister Kathleen passed away peacefully at 39, leaving me to ...

Five years after my lymphoma diagnosis, life looks normal on the outside; however, the fear of recurrence and the reality of ...

Bob Lane discusses his experience with prostate cancer, and describes what survivorship and cure means to him as someone ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural ...

Olalekan O. Oluwole discusses how CAR T-cell therapy is used to treat high-risk hematologic malignancies like lymphoma and ...